{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:16:07Z","timestamp":1774019767572,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T00:00:00Z","timestamp":1636848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T00:00:00Z","timestamp":1636848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Many patients with polymyositis (PM) or dermatomyositis (DM) have circulating myositis-specific antibodies (MSAs). Interstitial lung disease (ILD) is a common manifestation of PM\/DM, and it can even precede the onset of characteristic muscle or skin manifestations. Furthermore, there appear to be some patients with ILD and circulating MSAs who do not develop muscle or skin disease even after prolonged follow-up. We sought to determine whether ILD is equally or more common than myositis or dermatitis at the time of initial detection of MSAs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We identified all patients found to have circulating MSAs at our institution over a 4-year period and assessed for the presence of lung, muscle, and skin disease at the time of initial detection of MSAs. Among those found to have ILD, we compared demographic and clinical features, chest CT scan findings, and outcomes between those with PM\/DM-associated ILD and those with ILD but no muscle or skin disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 3078 patients were tested for MSAs, and of these 40 were positive. Nine different MSAs were detected, with anti-histidyl tRNA synthetase (anti-Jo-1) being the most common (35% of MSAs). Among patients with positive MSAs, 86% were found to have ILD, compared to 39% and 28% with muscle and skin involvement, respectively (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Fifty percent of all MSA-positive patients had isolated ILD, with no evidence of muscle or skin disease. Those with isolated ILD were more likely to be older and have fibrotic changes on chest CT, less likely to receive immunomodulatory therapy, and had worse overall survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this study we found that individuals with circulating MSAs were more likely to have ILD than classic muscle or skin manifestations of PM\/DM at the time of initial detection of MSAs. Our findings suggest that the presence of ILD should be considered a disease-defining manifestation in the presence of MSAs and incorporated into classification criteria for PM\/DM.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12890-021-01737-7","type":"journal-article","created":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T20:40:43Z","timestamp":1636922443000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies"],"prefix":"10.1186","volume":"21","author":[{"given":"Abhinav K.","family":"Misra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terrance T.","family":"Healey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward V.","family":"Lally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3205-026X","authenticated-orcid":false,"given":"Barry S.","family":"Shea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,14]]},"reference":[{"key":"1737_CR1","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/BOR.0000000000000329","volume":"28","author":"M Fujimoto","year":"2016","unstructured":"Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol. 2016;28:636\u201344.","journal-title":"Curr Opin Rheumatol"},{"key":"1737_CR2","doi-asserted-by":"publisher","first-page":"322","DOI":"10.7861\/clinmedicine.17-4-322","volume":"17","author":"A Oldroyd","year":"2017","unstructured":"Oldroyd A, Lilleker J, Chinoy H. Idiopathic inflammatory myopathies\u2014a guide to subtypes, diagnostic approach and treatment. Clin Med (Lond). 2017;17:322\u20138.","journal-title":"Clin Med (Lond)"},{"key":"1737_CR3","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","volume":"70","author":"LA Love","year":"1991","unstructured":"Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991;70:360\u201374.","journal-title":"Medicine (Baltimore)"},{"key":"1737_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971\u201382.","journal-title":"Lancet"},{"key":"1737_CR5","first-page":"692","volume":"16","author":"GJ Hengstman","year":"2004","unstructured":"Hengstman GJ, van Engelen BG, van Venrooij WJ. Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol. 2004;16:692\u20139.","journal-title":"Curr Opin Rheumatol"},{"key":"1737_CR6","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.4049\/jimmunol.162.4.2315","volume":"162","author":"M Hirakata","year":"1999","unstructured":"Hirakata M, Suwa A, Nagai S, Kron MA, Trieu EP, Mimori T, Akizuki M, Targoff IN. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol. 1999;162:2315\u201320.","journal-title":"J Immunol"},{"key":"1737_CR7","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/rheumatology\/kem045","volume":"46","author":"Z Betteridge","year":"2007","unstructured":"Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford). 2007;46:1005\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"1737_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/08916930400022681","volume":"38","author":"A Ghirardello","year":"2005","unstructured":"Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Bendo R, Gambari PF, Doria A. Anti-Mi-2 antibodies. Autoimmunity. 2005;38:79\u201383.","journal-title":"Autoimmunity"},{"key":"1737_CR9","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.21023","volume":"52","author":"S Sato","year":"2005","unstructured":"Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, Nishikawa T, Oddis CV, Ikeda Y. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571\u20136.","journal-title":"Arthritis Rheum"},{"key":"1737_CR10","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1002\/art.22862","volume":"56","author":"Z Betteridge","year":"2007","unstructured":"Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum. 2007;56:3132\u20137.","journal-title":"Arthritis Rheum"},{"key":"1737_CR11","doi-asserted-by":"publisher","first-page":"9507","DOI":"10.1073\/pnas.83.24.9507","volume":"83","author":"WH Reeves","year":"1986","unstructured":"Reeves WH, Nigam SK, Blobel G. Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci U S A. 1986;83:9507\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1737_CR12","doi-asserted-by":"crossref","unstructured":"Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, Miller FW, Rider LG, Childhood Myositis Heterogeneity Study G, International Myositis Collaborative Study G. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006; 54:3682\u20133689.","DOI":"10.1002\/art.22164"},{"key":"1737_CR13","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","volume":"71","author":"Y Ichimura","year":"2012","unstructured":"Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, Inokoshi Y, Kawai K, Kanekura T, Habuchi M, Igarashi A, Sogame R, Hashimoto T, Koga T, Nishino A, Ishiguro N, Sugimoto N, Aoki R, Ando N, Abe T, Kanda T, Kuwana M, Takehara K, Fujimoto M. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;71:710\u20133.","journal-title":"Ann Rheum Dis"},{"key":"1737_CR14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","volume":"14","author":"NJ McHugh","year":"2018","unstructured":"McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol. 2018;14:290\u2013302.","journal-title":"Nat Rev Rheumatol"},{"key":"1737_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","volume":"121","author":"H Hozumi","year":"2016","unstructured":"Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A, Enomoto N, Inui N, Nakamura Y, Hosono Y, Imura Y, Mimori T, Suda T. Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease. Respir Med. 2016;121:91\u20139.","journal-title":"Respir Med"},{"key":"1737_CR16","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00296-016-3494-3","volume":"36","author":"P Srivastava","year":"2016","unstructured":"Srivastava P, Dwivedi S, Misra R. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis. Rheumatol Int. 2016;36:935\u201343.","journal-title":"Rheumatol Int"},{"key":"1737_CR17","doi-asserted-by":"crossref","unstructured":"Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP, Lilleker JB, Vencovsky J, Chazarain L, Danko K, Nagy-Vincze M, Bodoki L, Dastmalchi M, Ekholm L, Lundberg IE, McHugh N, Contributors UK. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019;101:48\u201355.","DOI":"10.1016\/j.jaut.2019.04.001"},{"key":"1737_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1136\/thx.2006.069237","volume":"63","author":"I Tillie-Leblond","year":"2008","unstructured":"Tillie-Leblond I, Wislez M, Valeyre D, Crestani B, Rabbat A, Israel-Biet D, Humbert M, Couderc LJ, Wallaert B, Cadranel J. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax. 2008;63:53\u20139.","journal-title":"Thorax"},{"key":"1737_CR19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0049-0172(96)80026-6","volume":"26","author":"AW Friedman","year":"1996","unstructured":"Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum. 1996;26:459\u201367.","journal-title":"Semin Arthritis Rheum"},{"key":"1737_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2169\/internalmedicine.49.2889","volume":"49","author":"Y Koreeda","year":"2010","unstructured":"Koreeda Y, Higashimoto I, Yamamoto M, Takahashi M, Kaji K, Fujimoto M, Kuwana M, Fukuda Y. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med. 2010;49:361\u20139.","journal-title":"Intern Med"},{"key":"1737_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/ard.2003.006122","volume":"63","author":"M Fathi","year":"2004","unstructured":"Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004;63:297\u2013301.","journal-title":"Ann Rheum Dis"},{"key":"1737_CR22","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/art.23571","volume":"59","author":"M Fathi","year":"2008","unstructured":"Fathi M, Vikgren J, Boijsen M, Tylen U, Jorfeldt L, Tornling G, Lundberg IE. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum. 2008;59:677\u201385.","journal-title":"Arthritis Rheum"},{"key":"1737_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1136\/bmj.289.6438.151","volume":"289","author":"RM Bernstein","year":"1984","unstructured":"Bernstein RM, Morgan SH, Chapman J, Bunn CC, Mathews MB, Turner-Warwick M, Hughes GR. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J (Clin Res Ed). 1984;289:151\u20132.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"1737_CR24","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/qjmed\/77.1.1019","volume":"77","author":"C Marguerie","year":"1990","unstructured":"Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, Walport MJ. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990;77:1019\u201338.","journal-title":"Q J Med"},{"key":"1737_CR25","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1172\/JCI116493","volume":"91","author":"IN Targoff","year":"1993","unstructured":"Targoff IN, Trieu EP, Miller FW. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest. 1993;91:2556\u201364.","journal-title":"J Clin Invest"},{"key":"1737_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0002-9343(90)90149-8","volume":"88","author":"IN Targoff","year":"1990","unstructured":"Targoff IN, Arnett FC. Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med. 1990;88:241\u201351.","journal-title":"Am J Med"},{"key":"1737_CR27","doi-asserted-by":"crossref","unstructured":"Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, Garcia-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, International Myositis Classification Criteria Project Consortium tER, the Juvenile Dermatomyositis Cohort Biomarker S, Repository. 2017 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol. 2017;69:2271\u20132282.","DOI":"10.1002\/art.40320"},{"key":"1737_CR28","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/art.10794","volume":"47","author":"I Marie","year":"2002","unstructured":"Marie I, Hachulla E, Cherin P, Dominique S, Hatron PY, Hellot MF, Devulder B, Herson S, Levesque H, Courtois H. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47:614\u201322.","journal-title":"Arthritis Rheum"},{"key":"1737_CR29","doi-asserted-by":"crossref","unstructured":"Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL, Mosca M, Noth I, Richeldi L, Strek ME, Swigris JJ, Wells AU, West SG, Collard HR, Cottin V, CTD-ILD EATFoUFo. An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46:976\u2013987.","DOI":"10.1183\/13993003.00150-2015"},{"key":"1737_CR30","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/0961203316651748","volume":"25","author":"R Nakashima","year":"2016","unstructured":"Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus. 2016;25:925\u201333.","journal-title":"Lupus"},{"key":"1737_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","volume":"52","author":"M Satoh","year":"2017","unstructured":"Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EK. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol. 2017;52:1\u201319.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1737_CR32","doi-asserted-by":"crossref","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendia-Roldan I, Selman M, Travis WD, Walsh S, Wilson KC, American Thoracic Society ERSJRS, Latin American Thoracic S. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44\u2013e68.","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"1737_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1465-9921-15-10","volume":"15","author":"K Oda","year":"2014","unstructured":"Oda K, Ishimoto H, Yatera K, Naito K, Ogoshi T, Yamasaki K, Imanaga T, Tsuda T, Nakao H, Kawanami T, Mukae H. High-resolution CT scoring system-based grading scale predicts the clinical outcomes in patients with idiopathic pulmonary fibrosis. Respir Res. 2014;15:10.","journal-title":"Respir Res"},{"key":"1737_CR34","doi-asserted-by":"publisher","first-page":"e180029","DOI":"10.1148\/ryct.2019180029","volume":"1","author":"A Chahal","year":"2019","unstructured":"Chahal A, Sharif R, Watts J, de Andrade J, Luckhardt T, Kim YI, Ramchandran R, Sonavane S. Predicting outcome in idiopathic pulmonary fibrosis: addition of fibrotic score at thin-section CT of the chest to gender, age, and physiology score improves the prediction model. Radiol Cardiothorac Imaging. 2019;1:e180029.","journal-title":"Radiol Cardiothorac Imaging"},{"key":"1737_CR35","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1378\/chest.12-2623","volume":"144","author":"JJ Mooney","year":"2013","unstructured":"Mooney JJ, Elicker BM, Urbania TH, Agarwal MR, Ryerson CJ, Nguyen MLT, Woodruff PG, Jones KD, Collard HR, King TE Jr, Koth LL. Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. Chest. 2013;144:586\u201392.","journal-title":"Chest"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-021-01737-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-021-01737-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-021-01737-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T04:38:12Z","timestamp":1673757492000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-021-01737-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,14]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1737"],"URL":"https:\/\/doi.org\/10.1186\/s12890-021-01737-7","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,14]]},"assertion":[{"value":"24 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Lifespan-Rhode Island Hospital Institutional Review Board (IRB). The need for informed consent was waived by the Lifespan-Rhode Island Hospital IRB. No additional administrative permissions or licenses were acquired to access the patient data used in this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"370"}}